Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

Yubero, A; Estévez, P; Barquín, A; Sánchez, L; Santaballa, A; Pajares, B; Reche, P; Salvador, C; Manso, L; Márquez, R; González-Martín, A

Yubero, A (通讯作者)，Hosp Clin Univ Lozano Blesa, Avda C San Juan Bosco 15, Zaragoza 50009, Spain.

GYNECOLOGIC ONCOLOGY REPORTS, 2023; 48 ():

Abstract

The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-gra......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索